All Updates

All Updates

icon
Filter
Partnerships
ACT Genomics and LSI Medience sign MOU for genomic and clinical testing in Japan
Precision Medicine
Jul 1, 2024
This week:
Partnerships
MGI Tech and Predica Diagnostics collaborate to develop Predica's targeted RNA sequencing tests
Precision Medicine
Jul 11, 2024
Partnerships
Renalytix partners with Steno Diabetes Center to advance precision medicine solutions for diabetes and chronic kidney disease
Precision Medicine
Jul 11, 2024
Partnerships
Myriad Genetics and Personalis cross-license patents for tumor-informed cancer treatment tests
Precision Medicine
Jul 11, 2024
Funding
Element Biosciences raises USD 277 million in Series D funding to commercialize AVITI DNA sequencer and support AVITI24 launch
Precision Medicine
Jul 11, 2024
Funding
Jacobi Robotics raises USD 5 million in seed funding to expand capacity
Smart Factory
Jul 11, 2024
M&A
Formlabs acquires Micronics for undisclosed sum to develop next-generation SLS printers
Additive Manufacturing
Jul 11, 2024
Partnerships
Anthropic partners with Amazon Bedrock to fine-tune Claude 3 Haiku model
Foundation Models
Jul 11, 2024
Funding
Lemon.markets raises EUR 12 million in funding to support growth
FinTech Infrastructure
Jul 11, 2024
M&A
Kipu Quantum acquires PlanQK platform to enhance accessibility to quantum computing solutions
Quantum Computing
Jul 11, 2024
Partnerships
Quantinuum and STFC Hartree Centre partner to enhance quantum computing accessibility in UK
Quantum Computing
Jul 11, 2024
Precision Medicine

Precision Medicine

Jul 1, 2024

ACT Genomics and LSI Medience sign MOU for genomic and clinical testing in Japan

Partnerships

  • ACT Genomics has partnered with LSI Medience, a subsidiary of PHC Holdings, to explore collaboration opportunities on genomic and clinical testing services tailored to the Japanese healthcare sector.

  • The partnership seeks to integrate genomic profiling into clinical research practices, providing personalized information to Japanese researchers. By utilizing ACT Genomics' expertise in genomic profiling technologies and LSI Medience's robust clinical testing services, it aims to accelerate technological innovation in the field. Once determined, specific initiatives and projects pertaining to the collaborative efforts will be announced in the future.

  • Headquartered in Taiwan, ACT Genomics is a global oncology solution provider specializing in precision oncology through next-generation sequencing (NGS) technology. The company offers a range of genomic profiling services that aid in cancer treatment planning, immunotherapy evaluation, and cancer relapse and drug resistance monitoring. Its flagship product, ACTOnco+, is a comprehensive genomic profiling test for solid tumors, which received FDA clearance in January 2023, the first Asian company to achieve this milestone.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.